{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:12Z","timestamp":1792036812090,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cDengfeng\u201d Talent Training Program of Beijing Hospitals Authority","award":["DFL20240301"],"award-info":[{"award-number":["DFL20240301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01793-8","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:11:51Z","timestamp":1776078711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Chuanying","family":"Geng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"Supplement 1","key":"1793_CR1","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2025-2297","volume":"146","author":"S Ailawadhi","year":"2025","unstructured":"Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A, Manier S, Iida S, Hello S, Dhanda D, Ghodke P, et al. KarMMa-3 subgroup analysis in older patients with relapsed\/refractory multiple myeloma treated with idecabtagene vicleucel. Blood. 2025;146(Supplement 1):2297.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2025-94","volume":"146","author":"L Costa","year":"2025","unstructured":"Costa L, Oriol A, Dytfeld D, Manier S, Voorhees P, Lin Y, Htut M, Roeloffzen W, Ho PJ, Shah U, et al. Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed\/refractory multiple myeloma. Blood. 2025;146(Supplement 1):94.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2025-256","volume":"146","author":"K Patel","year":"2025","unstructured":"Patel K, Dhakal B, Kaur G, Maziarz R, Callander N, Sperling A, Schinke C, Jakubowiak A, Biran N, Sborov D, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: Updated results from iMMagine\u20131. Blood. 2025;146(Supplement 1):256.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1182\/blood-2025-2387","volume":"146","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhang M, Zhang Y, Fu S, Feng J, Su G, Song D, Chang C-W, Wang H, Guan S, et al. OL-101, a BCMA\/GPRC5D dual-targeting autologous CAR-T for relapsed\/ refractory multiple myeloma (R\/R MM): Results from a Phase I study. Blood. 2025;146(Supplement 1):2387.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1182\/blood-2025-269","volume":"146","author":"S Richard","year":"2025","unstructured":"Richard S, Gaballa M, Gregory T, Chhabra S, Anderson L, Costa L, Costello C, Goldsmith S, Hansen D, Rajeeve S, et al. Safety and efficacy of AZD0120, a BCMA\/CD19 dual-targeting CAR T-cell therapy, in relapsed\/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b\/2 study. Blood. 2025;146(Supplement 1):269.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2025-270","volume":"146","author":"C Graham","year":"2025","unstructured":"Graham C, Puliafito B, Raje N, Cirstea D, Branagan A, Yee A, Horick N, Cook D, Lindell K, Bernier D, et al. First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance. Blood. 2025;146(Supplement 1):270.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR7","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2025-2296","volume":"146","author":"J Du","year":"2025","unstructured":"Du J, Jin L, Qiang W, Guo P, He H, Fan X, Zhao X, Yuan D, Luo Y, LI Z. A first-in-human study of CT0596, an allogeneic CAR T-cell therapy targeting BCMA, in patients with relapsed\/refractory multiple myeloma. Blood. 2025;146(Supplement 1):2296.","journal-title":"Blood"},{"issue":"Supplement 2","key":"1793_CR8","doi-asserted-by":"publisher","first-page":"LBA","DOI":"10.1182\/blood-2025-LBA-1","volume":"146","author":"S Harrison","year":"2025","unstructured":"Harrison S, Ho PJ, Lim S-L, Talam S, Pahl H, Dingar D, Currence S, Quigley T, Spencer A. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146(Supplement 2):LBA\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2025-254","volume":"146","author":"B Chen","year":"2025","unstructured":"Chen B, Shao X, Jin Y, Xu Y, Shi Q, Guan C, Shen X, Li P, Wu Y, Zeng H, et al. Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm, phase 1 study(fumanba-2). Blood. 2025;146(Supplement 1):254.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1182\/blood-2025-2293","volume":"146","author":"W Yan","year":"2025","unstructured":"Yan W, Du C, Zou H, Zhang S, Deng S, Xu Y, Yi S, Zou D, Qiu L, An G. BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001). Blood. 2025;146(Supplement 1):2293.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR11","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1182\/blood-2025-4068","volume":"146","author":"Y Liu","year":"2025","unstructured":"Liu Y, Sui W, Qiu L, An G. CAC-MM-001: Anti-BCMA CAR-T therapy followed by autologous stem cell transplantation and second CAR-T (CART-ASCT-CART2) in newly diagnosed multiple myeloma patients with P53 gene abnormalities. Blood. 2025;146(Supplement 1):4068.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1793_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood-2025-258","volume":"146","author":"J Du","year":"2025","unstructured":"Du J, Qiang W, Lu J, Jia Y, He H, Liu J, Guo P, Yang Y, Feng Z, Jin L, et al. A dual targeting BCMA and CD19 fastcar-t (GC012F\/AZD0120) as first-line therapy for newly diagnosed multiple myeloma. Blood. 2025;146(Supplement 1):258.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01793-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01793-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01793-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:11:52Z","timestamp":1776078712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01793-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1793"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01793-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}